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Abstract
Due to the low fidelity of the RNA-dependent RNA polymerase, Hepatitis C virus (HCV) mutates quite frequently. There
are seven genetically divergent genotypes (GTs) distributed in the world, each of which contains several closely related
subtypes. The peer-reviewed literatures reporting the prevalence rate of HCV GTs in Chinese hospitalized patients were
identified by systematic searching of three electronic databases, and the prevalence rates were pooled through 137
qualified studies. The significant difference between HCV GT and HCV viral load and severity of hepatitis were analyzed
under Chi-squared or Fisher’s exact test. Data from epidemiological studies on hospitalized patients demonstrated that
HCV GTs 1–6 have been found in China, of which 1b (62.78%(95% CI: 59.54–66.02%)) and 2a (17.39% (95% CI: 15.67–19.
11%)) are the two predominant subtypes. HCV GTs and subtypes exhibits significant regional divergence. In North,
Northwest, Northeast, East (except Jiangxi province) and Central China (except Hunan province), HCV-1b, 2a remain the
two predominant subtypes; South China shows the most abundant genetic diversity that 14 subtypes were found, and
HCV-3 in the Southwest China remains higher prevalent subtype than the other regions. In addition, co-infection in
Liaoning province of Northeast China is the most diverse with 10 co-infection types, and Tibet has the highest rate of
co-infection. The associations between HCV GTs and patients group, severity of illness and antiviral treatment efficacy
were also discussed in this review.
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Background
Hepatitis C virus (HCV) is a globally distributed hepatic
virus with an estimated 130 to 150 million people (2 to 3%
of the world’s population) chronically infected world
widely [1, 2]. It has been reported that by 2025, HCV-
related mortality will be tripled [3]. HCV infection consti-
tutes over 70% of post-transfusion hepatitis (PTHC), and
is one of the leading causes of chronic liver disease, which
usually results in liver cirrhosis (LC), liver failure and
hepatocellular carcinoma (HCC) within 20 to 30 years fol-
lowing infection [4–6]. HCV incidence in China was
0.06‰, however, in some area such as in Fujian, reached
as high as 6.01% in 2010 [7]. HCV infection has become
the second major type of viral liver disease only next to
Hepatitis B virus (HBV) infection in China [8], and ex-
hibits great threat to public health.
Hepatitis C virus (HCV) was classified into genus Hepa-
civirus of family Flaviviridae [6]. Like other positive-
stranded RNA viruses, the HCV genome encodes a single
polyprotein with approximately 3000-amino-acids in
length with the following order: 5’-C-E1-E2-p7-NS2-NS3-
NS4A-NS4B-NS5A-NS5B-3’ [9], and flanks with 5’ and 3’
untranslated regions, which consists of 341 and 27 bases,
respectively [10]. HCV genome has high genetic hetero-
geneity with as much as 30% of sequence divergence [11].
Based on the sequence divergence, HCV was classified
into seven different genotypes (GTs) and more than 90
subtypes [6, 12]. The greatest genetic diversity was ob-
served within HCV-6, with 24 subtypes (6a-6xa) being
classified [13, 14].
In China, HCV GT distribution has been associated
with various geographical and demographic characteris-
tics. Due to the increasing mobility of the population
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and different transmission routs, HCV GTs distribution
changed gradually and co-infection with multiple subtypes
as well as genetic recombinant appeared frequently in
some regions. Most recently, three new subtypes have
been characterized in China: HCV-1b-2a, 1b-2 k and 6d-
6 k [15]. Since there is a paucity of data from large-sample
study of HCV GT distribution in China, this review aims
to describe the most comprehensive distribution of HCV
GTs in mainland China in order to facilitate personalized
treatment and to further understand the virology of HCV
for vaccine and antiviral drug development in China.
Methods
Literature search
The literature search on HCV GT detection among clin-
ical cases in mainland China was conducted using China
National Knowledge Infrastructure (CNKI), PubMed and
Wanfang Data (a Chinese professional academic data-
base developed by Wanfang data limited-liability Com-
pany) with the key words “HCV” or “Hepatitis C virus”;
“genotype” or “subtype”, “sequencing” or sequence ana-
lysis”; “transfusion transmitted disease” and “China” or
“Mainland China”. No language restrictions were applied.
Literature selection and data extraction
The inclusion criteria included: 1) The study was con-
ducted only in mainland China (Hong Kong, Taiwan and
Macao were excluded); 2) Studies involving the HCV
genotype and (or) subtype distribution; 3) The study ob-
ject were hospitalized patients; 4) Studies with clear
sample size.
The exclusion criteria were as follows: 1) studies with-
out exact sample size, publication year and methods; 2)
Overlapping or paradoxical studies: data from literature
were repeat or inconsistent between the context; 3) The
study objects were blood donors or intravenous drug
user; 4) HCV GTs prevalence rate in patients with HIV/
HCV co-infection; 5) Comments, reviews or conference
abstracts. When investigating the trends of HCV GT
spatio-temporal distributions, literatures without exact
study year were not included.
Statistical analysis
Pooled results for the prevalence rate of HCV GTs and
corresponding 95% CIs by metan command in Stata 12.0
were used to assess the HCV GTs distribution status
among hospitalized patients in China. The % of GT in
each study counted by the weighted method that the
contribution of each study was determined by number
of patients in the individual studies. The time trend of
HCV prevalence rate, and the significant difference be-
tween HCV GT and HCV viral load and severity of
hepatitis was performed using SPSS Statistics 17.0 based
on Chi-squared or Fisher’s exact test of crosstabs, and P
value <0.05 represents statistical significance.
Results
HCV GT distribution
A profile of HCV GT data
Related data were collected: 193 studies [6–8, 12, 13,
16–203] considering methods used for HCV genotyping
(Table 1); 137 clinical studies [7, 8, 12, 13, 16–146, 202,
203] with a total of 19712 HCV hospitalized cases con-
sidering prevalence rate of HCV subtypes [Fig. 1].
Commonly used molecular biology methods for HCV
genotyping include DNA sequence assay (a gold stand-
ard), type specific primers amplification method, restric-
tion fragment length polymorphism (RFLP), gene chip
assay, and probe hybridization. Multiple methods target-
ing different regions of the HCV genome have been used
for classifying GTs. The most accurate method is to se-
quence an appropriate coding region that varies enough
for phylogenetic analysis to distinguish genotypes and
subtypes [204, 205]. Although the 5’ untranslated region
(5’UTR) has most often been used by clinical laborator-
ies for routine genotyping considering its high level of
conservation, the 5’UTR is limited in its ability to dis-
criminate GT 6 from GT 1 and subtypes within GTs 1,
2, 3, 4, and 6 [14, 206]. Nowadays, the three most com-
monly used regions for determining the HCV GT and
subtypes are Core, E1, and NS5B [14, 207] with high ac-
curacy and sensitivity.
HCV GT distribution among clinical cases in mainland China
The dominant HCV GTs in most Asian countries are
HCV-1, 3 [208]. Although six GTs (GTs 1 to 6), 24 sub-
types (subtypes 1a, 1b, 1c, 2a, 2b, 2i, 2f, 2 k, 3a, 3b, 3 k,
4, 5a, 6a, 6b, 6d, 6e, 6 g, 6 h, 6 k, 6n, 6u, 6v, and 6w),
and a number of unassigned HCV variants have been de-
tected in China, over 95% of these isolates belong to five
major subtypes: 1b, 2a, 3a, 3b, and 6a [12, 177, 209–214].
The prevalence rate of HCV GTs in various regions of
mainland China was pooled, and corresponding 95% CIs
was also further tabulated (Table 2). Although HCV GTs
1–6 have been found in China, GTs 1b and 2a were the
two major HCV subtypes, accounting for 62.78% (95%
CI: 59.54–66.02%) and 17.39% (95% CI: 15.67–19.11%),
respectively. In 70% (22/30) of provinces, HCV-1b, 2a
are still the most prevalent. The major GTs in Jiangxi,
Guangdong, Hunan and Guangxi were 1b, 6a, while in
Yunnan, Sichuan, Guizhou and Chongqing were 1b, 3b.
In Yunnan Province, 3b and 1b was the predominant
HCV subtypes. HCV GT distribution also exhibits sig-
nificant region divergence (Fig. 2). The major subtypes
in North China, Northwest and Northeast were 1b and
2a, although 1a, 1c, 2b, 2c, 2i, 2 k, 3a, 3b, 3 k, 4, 6a were
also identified. In East and Central China, HCV-1b, 2a
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remain the two predominant subtypes except Jiangxi
and Hunan province with the popular subtypes 1b and
6a. In Southwest and South China, HCV-1b, 3b/6a was
the predominant subtype. South China region showed
the most abundant genetic diversity with 14 subtypes
(1a, 1b, 1c, 2a, 2b, 2f, 3a, 3b, 4, 5a, 6a, 6d, 6e, 6n) being
found, and HCV-3 in the Southwest remains higher
prevalent subtype than other regions, which was consist-
ent with previously published studies [212, 215].
HCV GT distribution reported by various Chinese re-
gions is experiencing a remarkable change over time. An
annual decrease of 1b, 2a, and an increase of GT 3a, 3b,
6n and 6a were reported in Henan, Jiangsu, Zhejiang,
Chongqing, Tianjin and Yunnan [13, 16, 25, 90, 136,
152, 191, 216, 217]. We also screened qualified lite-
ratures from the hospitalized cases, and three periods
(before 2005; 2005–2010; after 2010) were divided to
summary respective prevalence rate of HCV GT. Com-
parison of prevalence rate over time was then performed
to get the changing trend of HCV GT distribution. Our
results showed that in Southwest and South China,
HCV GT distribution experienced a significant change
(P < 0.05) (Table 3) that the proportion of subtypes 1b,
2a were decreasing and yet GT 3 were increasing over
time. In addition, HCV subtype 4, 5, 6v, 6d, 6u have
also been found in some areas of China in recent years
[191, 210, 211, 213, 218]. This changing trend may result
from the increasing population mobility, various transmis-
sion routes, and the improved sensitivity and specificity of
testing methods.
HCV GT characteristics of co-infection in China
Presence of multiple HCV subtypes, increasing of popu-
lation mobility and drug abusers, more convenient use
of hemodialysis and improved detection methods in-
crease the incidence of reported co-infection with mul-
tiple subtypes and genomic recombination. Till now, at
least 5 subtypes of co-infection have been reported in
China [170, 219].
In recent years, HCV GTs exhibit an increased per-
centage of co-infection, of which the most common in
China was 1b/2a co-infection, and GTs 2a/2b and 1b/2b
co-infection were occasionally reported, which may
affect the host immune responses and treatment out-
comes [220–222]. It was reported that among 1450
HCV RNA positive plasma (serum) samples collected
Table 1 Methods used for HCV genotyping in mainland China
Region Province Genotyping method Amplified fragment
Central China1* Hunan, Hubei, Henan Nested-PCR and sequence analysis, PCR-RDB, GT-
specific primers PCR method, gene chip assay
Core and E1, NS5B and/or Core-E1,
NS5B, 5’UTR, core
East China2* Shandong, Jiangsu,
Anhui, Jiangxi, Fujian,
Shanghai, Zhejiang
Nested-PCR and sequence analysis, RFLP, GT-
specific primers PCR method, gene chip assay,
Genotyping detection kit (DNA sequence assay),
PCR-RDB, Micro plate nucleic acid hybridization-
ELISA technique, LiPA
5’-UTR, core, NS5B
and/or core-E1, 5’-UTR and/or NS5B,
NS5B and C/E2, core and NS5B and
5’-UTR, E2, NS5B and E2
South China3* Guangdong, Guangxi,
Hainan
Nested-PCR and sequence analysis, GT-specific
primers PCR method, gene chip assay, PCR – RDB,
LiPA
NS5B and E1, core and NS5B, E1, NS5B, 5’-UTR and
NS5B
North China4* Beijing, Shanxi,
Tianjin, Hebei, IM
RFLP, Nested-PCR and sequence analysis, GT-





gene chip assay, RFLP, Nested-PCR and sequence
analysis, PCR-RDB, Type specific probe hybridization
method
5’-UTR, 5’UTR-core and E1-E2 and NS5B,
5’NCR-C and NS5B, core/E1 and
NS5B, E1/E2 and NS5B, 5’-UTR and Core,
core and E1, core, C/E1, NS5B
Northwest6* Gansu, Sha anxi, Xinjiang Nested-PCR and sequence analysis, RFLP, PCR-
RDB,GT-specific primers PCR method,LiPA,
restriction endonuclease cleaving method
E1 and NS5B, 5’NCR, NS5B
Northeast7* Liaoning, Heilongjiang,
Jilin
RFLP, Nested-PCR and sequence analysis, PCR –
RDB, type-specific primers PCR method, gene chip
assay
NS5, Core, 5’UTR, C and E1 and NS5
PCR-RDB: Polymerase chain reaction-reverse dot blot; RFLP: Restriction fragment length polymorphism
LiPA: Line probe hybridization method
1*. See reference [7, 16–30, 131, 155, 193]
2*. See reference [6, 8, 31–67, 132–139, 147–150, 156–166, 199, 201]
3*. See reference [12, 13, 67–82, 167–178, 202]
4*. See reference [83–89, 145, 151, 152, 179–182, 203]
5*. See reference [82, 90–102, 153, 179, 188–192, 194–198]
6*. See reference [103–120, 141–144, 146, 184–187]
7*. See reference [121–130, 140, 154, 183]
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randomly from general and infectious disease-specialized
hospitals of the capital city from all provinces (except
Taiwan), municipalities (except Chongqing), and autono-
mous regions (except Xinjiang), 11 was reported as HCV
co-infection. These co-infection with multiple subtypes in-
volved 1b, 2a and 6a, of which 1b/2a was the most com-
mon, accounting for 81.8% (9/11) and followed by 6a/2a
and 6a/1a, which is also the first time for HCV co-infection
in China that the GT 6a was found [223]. Patients who
repeatedly received blood, used to share needles as intra-
venous drug users (IDUs) and routinely performed dialysis
contributed significantly to multiple HCV genotypes/sub-
type co-infection in China [222, 224]. According to our
statistical analysis, co-infection in Liaoning province of
Northeast China is the most diverse with 10 co-infection
types, and Tibet has the highest rate of co-infection, which
might suggest that there had a relatively high proportion of
patents who would be a repeated recipient, an IDU, or a
dialysis patient. In addition, it was reported that HCV triple
infections kept a relatively high percentage in Gansu, of
which GTs 1a/1b/2a or 1a/1b/2c were more popular, ac-
counting for 20.6% (14/68) infections [186].
In addition, HCV subtype 6a was most common in pa-
tients with HIV/HCV co-infection, and was mainly
spread through intravenous drug use [225, 226].
HCV GTs and different population demographics
HCV GT distribution usually varied in different popula-
tions such as in blood donors, IDUs, hemodialysis patients
(HDs) and hepatitis patients. The distribution pattern
changes with the change of transmission modes [227].
Generally, transfusion transmitted HCV were strongly as-
sociated with subtypes 1b and 2a [89, 180, 181]. Encour-
agingly, the paid blood donation is not common in China
with the implementation of the Blood Donation Law in
1998. In voluntary blood donors, GTs 1b and 2a account
for the highest proportion [228], and HCV GT distribu-
tion exhibits significant geographical difference: The most
common GTs in Shanxi, Henan, Jiangsu, Anhui, Shanghai,
Shaanxi, Hebei and Xinjiang are 1b and 2a; the prevalent
GTs in Guangdong and Fujian Province are 1b and 6a; the
dominant GTs in Chongqing and Yunnan are 3a and 2a/
3b; GTs 1b, 1a and 1b, 3b are most common in Guangxi
and Qinghai, respectively. In addition, the proportion of
subtypes 1b and 2a in volunteers decreased in recent
years, and yet subtypes 3 and 6 increased [179, 229]. Some
reasons may explain this GT shift: 1) Increasing of drug
abuser and commercial sex activity resulted in transmis-
sion from high risk population to general population; 2)
Upgrade of genotyping methods accompanied by new
HCV GTs and subtypes. Among IDUs, HCV-1a, 1b, 2a,
3a, 3b, 6a, 6n and 6u have been found, of which HCV-6a
and 3b/3a/1b were the most popular GTs. In HD patients,
the prevalence of genotype 1 is the highest, and HCV GTs
among HDs are very complex with the co-infection ac-
counting for a big proportion [224, 230, 231], which may
be ascribed to long-term dialysis, repeatedly blood trans-
fusion and iatrogenic factors. In addition, some cases of
subtype 2a are found in individuals with high risk sexual
behaviors, while 1b was more popular in clinical cases
[194, 232, 233].
According to statistic results, discrepancy results
displayed the association between HCV GTs and
gender, age in infected patients. Most studies showed
no statistical difference between HCV GT and gen-
der [7, 20, 31, 136, 137, 234], while the rest displayed
significant difference, of which the proportion of subtype
1b was higher in male than in female. And on the con-
trary, subtype 2a showed the opposite distribution [13, 32,
40, 83, 156]. The reasonable explanation for this signifi-
cant difference may be that different genders exhibit dif-
ferent immune response against HCV infections with
different GTs. For the relationship between HCV GT and
age, most studies reported no statistical difference. How-
ever, there were a few studies showed that GT 1 and 2
were more common in the older group while GT 3 and 6
in the younger group [78, 137, 235]. The reason may be
ascribed to be that the transmission routs are more in-
clined to blood transfusion in the elder group and the
main GTs were HCV-1 and 2. While in the younger
Fig. 1 Flow diagram of summary of search strategy
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Table 2 HCV GT/subtypes distribution in mainland China
Study location Province The dominated two GTs in each province The other distributed GTs
East China Shandong 1b 67.74% (95% CI: 60.94–74.53%) 6a,1a,3a,3b
2a 27.57% (95% CI: 22.76–32.38%)
Jiangsu 1b 75.77% (95% CI: 72.47–79.07%) 2i, 3b, 3a, 1a, 6a, 2b, 6 h, 1c, 6b
2a 11.01% (95% CI: 8.77–13.25%)
Anhui 1b 66.45% (95% CI: 47.57–85.32%) 3b, 3a, 6 k, 1a, 2b
2a 16.52% (95% CI: 8.77–24.28%)
Zhejiang 1b 67.95% (95% CI: 56.70–79.20%) 3b, 3a, 6a, 1a
2a 11.06% (95% CI: 9.06–13.05%)
Jiangxi 1b 70.28% (95% CI: 52.38–88.19%) 2a, 2b, 3a,3b
6a 21.82% (95% CI: 10.90–32.73%)
Fujian 1b 66.17% (95% CI: 33.93–98.4%) 3b, 6a, 3a, 2b,6b
2a 17.42% (95% CI: 11.45–23.39%)
Shanghai 1b 80.14% (95% CI: 69.64–90.63%) 3a,3b,1a,6n,6a
2a 13.28% (95% CI: 8.22–18.35%)
South China Guangdong 1b 63.91% (95% CI: 58.48–69.34% 2a, 3b, 3a, 1a, 6e, 6n, 4, 2b, 5a,
6a 17.32% (95% CI: 14.44–20.21%) 1c, 2f
Guangxi 1b 56.46% (95% CI: 50.73–62.20%) 3b, 1a, 2a, 3a, 6d
6a 12.88% (95% CI: 9.00–16.75%)
Hainan 1b 62.50% (95% CI: 51.32–73.68%) 3a
2a 29.17% (95% CI: 18.67–39.67%)
North China Beijing 1b 70.41% (95% CI: 65.95–74.87%) 1a,2b,3a
2a 22.15% (95% CI: 17.22–27.08%)
Hebei 1b 46.56% (95% CI: 40.69–52.44%) 1a,2b,3a
2a 36.69% (95% CI: 30.05–43.34%)
Shanxi 1b 67.22% (95% CI: 57.44–77.00%) 1a,3a
2a 13.51% (95% CI: 6.37–20.65%)
Tianjin 1b 84.21% (95% CI: 72.62%-95.8%)
2a 13.16% (95% CI: 2.41–23.91%)
Inner Mongolia 1b 63.27% (95% CI: 38.34–88.20%) 3a,1a
2a 33.33% (95% CI: 11.97–54.70%)
Central China Hunan 1b 41.04% (95% CI: 33.71–48.37%) 3b,2a,3a,5a
6a 18.50% (95% CI: 12.71–24.28%)
Hubei 1b 74.08% (95% CI: 66.69–81.47%) 3b, 6a, 3a, 1a,2b,6b
2a 12.68% (95% CI: 8.91–16.46%)
Henan 1b 78.57% (95% CI: 62.47–94.66%) 6a,3a,3b,1a
2a 14.26% (95% CI: 5.71–22.8%)
Southwest Sichuan 1b 78.84% (95% CI: 73.01–84.66%) 2a
3b 8.47% (95% CI: 4.50–12.43%)
Yunnan 3b 49.50% (95% CI: 38.01–60.98%) 3a, 2a, 6n, 6a
1b 20.52% (95% CI: 16.31–24.73%)
Tibet 1b 49.63% (95% CI: 41.27–58.0%) 1a
2a 16.38% (95% CI: −5.30–38.06%)
Guizhou 1b 35.22% (95% CI: 30.92–39.52%) 6a, 3a, 2a, 1a, 2b, 6d
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group, the patients were mainly infected by HCV-3 and 6
via intravenous drug abuse and high risk sexual behaviors.
However, one study in 2012 showed that subtype 1 was
found more often in younger patients (<40) [125], and an-
other report showed no statistical difference between
HCV-2a and age [78]. In view of the above discrepancy re-
sults, a large-scale multiple-center study involved a wider
area is needed to clarify the association between HCV GT
and age or gender in China.
HCV GTs and viral loads
Many present studies were designed to determine the
association between HCV GTs and viral loads in chronic
hepatitis patients. It has been well known that HCV
genotype/subtype together with viral load variations dur-
ing treatment are very important to guide the therapeutic
strategies and relapse rates [236]. However, many discrep-
ant results were reported. Generally speaking, the higher
HCV RNA loads would cause more severe liver damage
with more obvious clinical manifestations [78]. The viral
load in patients chronically infected with HCV is associ-
ated with GTs that the level of HCV RNA in HCV-1 pa-
tients is higher than that in GT non-1, and HCV-1 and 6
is higher than HCV-2 and 3 [52, 77, 78, 96, 152, 237],
which might be due to more efficient viral replication of
GTs 1 and 6 [238–240]. Some foreign studies also re-
ported the similar results [241]. However, another study
reported that among patients with high viral load in
China, HCV 2a was more common than other GTs [113],
while some foreign studies reported that genotype 3 or 4
were found to be significantly higher viral load as com-
pared to other genotypes [242, 243]. In addition, higher
levels of viral load were also seen in HCV co-infection
[156]. Interestingly, some other studies found no sig-
nificant correlation between HCV GTs and viral loads
[31, 52, 78, 92, 101, 135, 153].
Considering these conflicting and complex results
above, we extracted the qualified literature [17, 18, 32,
33, 44, 83, 133, 135, 152, 202, 234, 244] from the
screened hospitalized patients to summary the related
cases in mainland China among different GTs based on
HCV RNA quantitative level (<106 copies/ml indicates
low viral load; ≥106 copies/ml indicates high viral load),
and performed the statistical analysis of between them.
The overall result showed significant statistical differ-
ence (P < 0.05), which indicate HCV GT is associated
with HCV viral load. No significant difference between
subtypes 2a and 3a was found, and the significant differ-
ence was found in the other subtypes (Table 4) that
HCV RNA level with subtypes 1b and 6a was higher
than 2a, 3a and 3b. Various factors may be taken into ac-
count: 1) Different viral replication ability among various
subtypes; 2) Regional GT distribution difference; 2)
HCV infection time was not restricted exactly and iden-
tified in the same or similar stage. Since high viral load
is difficult to treat than low viral load, we suggest precise
mechanism study should be performed to ascertain the
correlation between HCV genotypes and viral load and
to further design the therapeutic strategies.
HCV GTs and severity of hepatitis
The varied HCV GTs, subtypes and strains showed dif-
ferent degree of liver damage [83, 245, 246]. Subtype 1b,
which has more efficient viral replication ability and
Table 2 HCV GT/subtypes distribution in mainland China (Continued)
3b 21.93% (95% CI: 18.22–25.65%)
Chongqing 1b 32.21% (95% CI: 25.04–39.38%) 2a, 6a, 3a, 1a, 6b, 2b,3 k
3b 21.86% (95% CI: 7.99–35.73%)
Northwest Shaanxi 1b 50.74% (95% CI: 42.35–59.14%) 6a, 3a, 3b
2a 40.39% (95% CI: 32.15–48.62%)
Gansu 1b 56.07% (95% CI: 49.91–62.23%) 1c, 1a, 2c, 3a, 2b, 3b
2a 26.74% (95% CI: 16.44–37.03%)
Xinjiang 1b 62.71% (95% CI: 60.10–65.33%) 1a, 3a, 2b, 3b, 4, 6a
2a 18.10% (95% CI: 11.99–24.2%)
Qinghai 1b 49.08% (95% CI: 30.01–68.16%) 3b, 3a
2a 33.8% (95% CI: 26.84–40.76%)
Northeast Heilongjiang 1b 48.46% (95% CI: 41.29–55.62%) 2c, 2b, 1a, 3a
2a 37.73% (95% CI: 28.82–46.65%)
Liaoning 1b 44.87% (95% CI: 24.30–65.44%) 1a, 2i, 3a, 1c, 2b, 3b, 3 k, 2 k
2a 34.37% (95% CI: 11.24–57.50%)
Jilin 1b 56.44% (95% CI: 50.51–62.38%) 2b, 1a,3a
2a 31.96% (95% CI: 19.42–44.50%)
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poor prognosis and possesses major proportion of severe
liver disease (LD), is associated with HCV-related LC
and HCC [83, 88, 117, 158, 247] than non-1b subtypes.
The viral genome rapid replication is higher in patients
with GT 1 than that in other GTs. As a result, the conse-
quent liver histological grading and hepatitis progress
speed are considerably higher than those of GT 2 in-
fected patients, which would lead GT 1 more incline to
progress into HCC consistently with previous report
[87]. A study found that 5 patients with LC among 94
cases were all GT 1b [50], while 1a, 2a, 2b, 3a were more
common in chronic hepatitis patients without LC and
liver cancer [117, 248]. Patients infected with subtype 4
were also reported to be associated with the decompen-
sated liver complications [249], and this strong cytotoxic
effect may be associated with specific proteins encoded by
subtype-specific mutant genes [250, 251]. However, other
research showed that no significant differences were found
between HCV GTs and outcome of HCV infections
[31, 96, 128, 252]. Even so, consistent results reported
presently in and out of the county were found that 1b ac-
count for a larger proportion in moderate and severe
chronic hepatitis and LC than in acute, mild chronic hepa-
titis [253, 254], which may give us some suggestion that a
proactive clinical management should be important for
patients infected by HCV 1b. In addition, researches
launched outside China also showed that HCV-GT 3 was
associated with severe LD [255, 256].
Considering these conflicting and complex results
above, we extracted the qualified literature [8, 41, 59, 65,
83, 85, 87, 96, 97, 126, 128, 140] from the screened hos-
pitalized patients to summary the related cases in
Fig. 2 Map of HCV GT/subtypes distribution in various regions of mainland China. The seven colors in the map represent Chinese seven divisional
regions; the vertical bars indicate the top five subtypes in the different region of mainland China; the horizontal bars in the lower left corner indicates
the HCV genotypes and subtypes found in mainland China. The colored arrows marked in the below of genotype distribution in South and Southwest
China indicates the proportion trend change of HCV genotypes with time: subtypes 1b and 2a decreased with red arrow, and genotype 3 increased
with green arrow
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mainland China among different GTs based on sever-
ity of hepatitis (chronic hepatitis; cirrhosis; hepatocel-
lular carcinoma), and performed the statistical
analysis. The overall result showed significant differ-
ence (P < 0.05), which may indicate HCV GT is asso-
ciated with severity of hepatitis. Significant difference
was found between subtypes 1b and 2a, 3b, and the
significant difference was not found in the other sub-
types (Table 5). The possible reason for subtype 1b
being more inclined to cause severe LD than subtypes
2a and 3b may be that subtype 1b has stronger
pathogenicity and replication ability. In addition, the
host factor should also be considered. Based on the
above results, this may provide useful and instruc-
tional information for clinical treatment, and further
mechanism study may be badly needed to clarify the
association between HCV GTs and severity of
hepatitis.
HCV GTs and antiviral treatment efficacy
In China, the current standard-of-care (SOC) for the
treatment of patients chronically infected with HCV
is the combination therapy of PEGylated interferon
alpha and ribavirin (PEG-IFN and RBV, PR); however,
HCV GT is an important viral factor to predict thera-
peutic response and duration of treatment [257, 258].
Various genotypes of HCV have showed different
treatment effects. Patients with GT 2 and 3 can
achieve relative high SVR of 70–80%, yet patients
with GT 1 and 4 showed bad effect with the low SVR
of 40–50% [259–262]. This may be ascribed to the
different pathogenicity and replication ability of HCV
with different GTs and the host cell factor [263, 264].
However, the mechanism still need to be clarified in
the future, and some previous studies have reported
that this may be associated with increased amount or
mutation of E2 protein and the binding of NS5A pro-
tein to the protein kinase (PKR) [265, 266], a kind of
antiviral protein normally induced by IFN during
treatment.
With the development of new potent DAA and its com-
binations, the cure rate of HCV infection reaches >90% in
almost all HCV GTs and stages of LD [267, 268]. Espe-
cially, Epclusa, the first oral fixed-dose combination,
shows high SVR for all six major HCV genotypes, and
even in patients with decompensated cirrhosis, the SVR12
can achieve 94% [269]. Actually, China has completed the
clinical trials of some DAA drugs that sofosbuvir - dacla-
tasvir or Harvoni, daclatasvir + asunaprevir, Ledipasvir/
sofosbuvir and sofosbuvir + PEG/RBV are all safe and ef-
fective in Chinese patients with chronic hepatitis C [270].
Unfortunately, this DAA combination therapy is not cost-
effective and for the moment, PR remains a good alterna-
tive to treat Chinese patients chronically infected with
HCV with above 80% SVR which is higher than that in
Europe and America [271].
Table 3 Proportion change significance of HCV GT distribution
with time in South and Southwest China
Region Subtype Year Proportion P
South China
1b Before 2005 63.35% (159/251) <0.05
2005–2010 63.09% (400/634)
After 2010 55.00% (363/660)
2a Before 2005 14.34% (36/251) <0.05
2005–2010 8.83% (56/634)
After 2010 9.39% (62/660)
3 Before 2005 6.28% (12/191) <0.05
2005–2010 3.55% (45/1268)
After 2010 8.08% (91/1126)
Southwest 1b Before 2005 36.99% (54/146) <0.05
2005–2010 18.98% (41/216)
After 2010 35.23% (167/474)
2a Before 2005 21.92% (32/146) <0.05
2005–2010 6.48% (14/216)
After 2010 3.04% (11/362)
3 Before 2005 11.21% (25/223) <0.05
2005–2010 31.71% (137/432)
After 2010 18.88% (179/948)
P < 0.05 indicates significant difference
Table 4 Comparison of RNA levels of HCV with different subtypes







(1) 1b and 2a, 3a, 3b: P < 0.05 (2) 2a and 3a: P > 0.05; 2a and 3b, 6a
P < 0.05 (3) 3a and 3b, 6a: P < 0.05 (4) 3b and 6a: P < 0.05
Table 5 Comparison of severity of Hepatitis with different
genotypes
Subtypes Degree of liver disease
chronic hepatitis liver cirrhosis hepatocarcinoma
1aa 8 1 1
1b 395 165 46




(1) 1a and 1b, 2a, 3a, 3b: P > 0.05 (2) 1b and 2a, 3b: P < 0.05; 1b and 3a: P > 0.05
(3) 2a and 3a, 3b: P > 0.05 (4) 3a and 3b: P > 0.05
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Conclusion
To sum up, HCV GTs and subtypes showed significant
geographical distribution divergence in China. Along
with the increasing mobility of the population, the HCV
genotype distribution changes gradually. HCV GT distri-
bution and co-infection data from our comprehensive
statistical analysis in Chinese patient population provide
important diagnostic and prognostic information for
more effective treatment of HCV infections. In addition,
more attention should be paid to intravenous drug abus-
ing, which may have become a new risk factor for HCV
transmission in China. Above all, it is urgently need to
launch large-scale multi-center studies to discover the
associations between HCV genotypes/subtypes and some
clinical and viral factors described above. All those infor-
mation are important to implement personalized and
precision medicine in China for HCV infections and the
relative hepatitis.
Abbreviations
HCV: Hepatitis C virus; ETVR: End of treatment virological response;
GTs: Genotypes; HCC: Hepatocellular carcinoma; HDs: Hemodialysis patients;
IDUs: Intravenous drug users; LC: Liver cirrhosis; LD: Sever liver disease;
LiPA: Line probe hybridization method; PCR-RDB: Polymerase chain reaction-
reverse dot blot; PR: PEGylated interferon alpha and ribavirin; PTHC: Post-





This study was supported by Natural Science Foundation of China
(81572089).
Availability of data and materials
Please contact author for data requests.
Authors’ contributions
YZ carried out the study concept, data collection, analysis and drafting the
manuscript. MH has full access to all of the data in the study and takes
responsibility for the integrity of the data and the accuracy of the data
analysis. LM C gave an improved suggestion about the whole article. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Institute of Blood Transfusion, Peking Union Medical College, Chinese
Academy of Medical Sciences, Chengdu 610052, China. 2Sichuan Blood
Safety and Blood Substitute, International Science and Technology
Cooperation Base, Chengdu 610052, China. 3Toronto General Research
Institute, University of Toronto, Toronto, ON, Canada.
Received: 5 September 2016 Accepted: 15 February 2017
References
1. Cai LN, Zhu SW, Zhou C, Wang YB, Jiang NZ, Chen H, Tang XY, Wang JH,
Chen X, Hu WJ, et al. Infection status of HBV, HCV and HIV in voluntary
blood donors of Chinese Nanjing area during 2010–2013. Zhongguo Shi
Yan Xue Ye Xue Za Zhi. 2014;22:1089–93.
2. C P, G A, J P, L F, Y H: Estimated Global Prevalence of Hepatitis C Virus
Infection. [J] Annual Meeting 2004.
3. Thomas DL. Global control of hepatitis C: where challenge meets
opportunity. Nat Med. 2013;19:850–8.
4. Bennett H, Waser N, Johnston K, Kao JH, Lim YS, Duan ZP, Lee YJ, Wei L,
Chen CJ, Sievert W, et al. A review of the burden of hepatitis C virus infection
in China, Japan, South Korea and Taiwan. Hepatol Int. 2015;9:378–90.
5. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology
and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;
61:S45–57.
6. Ye Y, Yan YS, Chen G, Yan PP, Zheng WX, Deng YQ, Yang XH, Wu SL, Zhang
ZS. Molecular epidemiology of hepatitis C virus among different groups of
people in the province of Fujian, China. Arch Virol. 2013;158:611–8.
7. Peng J, Lu Y, Liu W, Zhu Y, Yan X, Xu J, Wang X, Wang Y, Liu W, Sun Z.
Genotype distribution and molecular epidemiology of hepatitis C virus in
hubei, Central China. PLoS One. 2015;10:e0137059.
8. Zhang Lx, An Y, Zhang Xg, Liu Lw, Jinhong Y: Genotypre distribution of chronic
HCV infectors in Shandong. Pathogen Biol 2011:567–570
9. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev
Microbiol. 2007;5:453–63.
10. Reed KE, Rice CM. Overview of hepatitis C virus genome structure, polyprotein
processing, and protein properties. Curr Top Microbiol Immunol. 2000;242:55–84.
11. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Beall E,
Yap PL, Kolberg J, Urdea MS. Classification of hepatitis C virus into six major
genotypes and a series of subtypes by phylogenetic analysis of the NS-5
region. J Gen Virol. 1993;74(Pt 11):2391–9.
12. Gu L, Tong W, Yuan M, Lu T, Li C, Lu L. An increased diversity of HCV isolates
were characterized among 393 patients with liver disease in China representing
six genotypes, 12 subtypes, and two novel genotype 6 variants. J Clin Virol.
2013;57:311–7.
13. Guie’ X, Shaojing. W: Research on HCV genotype among HCV infectors in
Guangzhou. J Trop Med 2014:589-594 + 598.
14. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon
P, Inchauspe G, Kuiken C, Maertens G, et al. Consensus proposals for a
unified system of nomenclature of hepatitis C virus genotypes. Hepatology.
2005;42:962–73.
15. An Y, Wu T, Wang M, Lu L, Li C, Zhou Y, Fu Y, Chen G. Conservation in China
of a novel group of HCV variants dating to six centuries ago. Virology. 2014;
464–465:21–5.
16. Gu B, Huang H. HCV genotypes of Chenzhou and the correlation analysis of
viral load. Chin J Clin Hepatol. 2013;29:832–834.
17. Zhou Y, Yin F. Research on association between HCV viral load, genotype
and antiviral effect. Practical journal of liver disease. 2011;14:340–343.
18. Zhou Q, Li Y. HCV genotyping in Wuhan, and analysis of liver funcion in chronic
patients and blood index. Int J Lab Med. 2013;34:1693–1695.
19. Lu E, Tong Y. Analysis of HCV genotype in 273 HCV infectors. Xiangyang
vocational and technical college. 2015;14:27–29.
20. Song S, Gui W. HCV genotype analysis of 169 cases in Wuhan. Practical
journal of clinical medicine. 2015;19:36–38.
21. Huang Q, Cao J. HCV genotype detection with PCR-RDB in Wuhan. Chinese
Journal of Nosocomiology. 2011;21:2674–2676.
22. Wang J, Yuan W. Oligonucleotide array chip detection of hepatitis c virus
(HCV) genotype and clinical application. Chinese Journal of Laboratory
Medicine. 2005;28:1248–1252.
23. Bao A, Li Y, Tong Y, Zheng H, Wu W. HCV genotyping of chronic patients
and therapeutic effect evaluation in Hubei. J Mod Lab. 2013;28:13–6.
24. Wu Z, Li Y. HCV genotyping results of 254 cases in Wuhan. Journal of
Modern Laboratory Medicine. 2014;29:124–126.
25. Li W, Zeng Y. HCV genotype distribution research among chronic HCV infectors
in Henan. The diagnosis and treatment of practical magazine. 2015;29:538–539.
26. Cheng S, Zhang B, Zhao L, Guo R, Xu Y, Li W, Fang J. HCV genotyping for
HCV carrier donors and HCV patients. Chinese Journal of Misdiagnostics.
2003;3:1330–1331.
Zhang et al. Virology Journal  (2017) 14:41 Page 9 of 14
27. Cui W, Sun G, Xiao Z, Liu J, Xing W, Wang Z: HCV genotype analysis of 121
HCV patients in Henan. Chin J Health Lab Technol. 2013;23:2220–2223.
28. Liu X, Wang D. HCV genotyping in Henan. World Chin J Dig. 2000;8:922–923.
29. Cui W, Xue X, Liu C, Sun G, Liu J, Fan P, Tai S, Sun D, Xing W. HCV infection status
and genotyping analysis in Henan 2012. Chin J Prev Med. 2013;47:518–22.
30. Huo Y, Xu D. HCV genotyping among HCV patientsin Xi'an and Zhengzhou.
J Fourth Mil Med Univ. 2002;23:749–751.
31. Shi C, Huang Y. HCV genotype research in Qingdao. Acta Academiae
Medicinae Qingdao Universitatis. 2014;50:230–232.
32. Xu W, Liu L. Hepatitis c virus (HCV) genotypes in shandong district and the
analysis of related factors. Journal of Shandong University. 2010:140-141 + 145.
33. Liu Y, Tian W. HCV genotyping research among 153 Han Chinese people in
Shandong. Laboratory Medicine and Clinic. 2014;11:2649–2650.
34. Zhang L, Wang L, Xu W. Hepatitis c virus genotype and serum credits type
research in Shandong. Chin J Clin Hepatol. 2005;21:215–216.
35. Zhang G, Pu S, Yu X. Research on HCV genotyping in Yantai, Shandong. The
Experimental and Clinical Virology Journal. 2012;26:259-262.
36. Yu X, Sun S, Jiang Y: HCVgenptyping distribution ans its clinical significance
in Yantai, Sandong. Medical Laboratory Science and Clinics. 2013;24:6-9.
37. Zhao W, Liu W. A preliminary study on HCV genotyping using Hepatitis
diagnostic chip. Chinese Medical Journal. 2002;82:28–32.
38. Zhang Y, Sun N, Huang Z. Research on HCV genotyping in Jiangsu. Jiangsu
Medical Journal. 2004;30:463–464.
39. Lu R, Huang L. Molecular epidemiology of HCV in Nantong, Jiangsu. Journal
of Nantong University. 2015;35:30–33.
40. Xu K: hepatitis c virus genotype distribution and coated area variation study
in Yixing, Jiangsu Master. Nanjing Medical University. 2006.
41. Shen L, Gu X. HCV genotype in Nanjing, HCV RNA and clinical prognosis.
Jiangsu Medical Journal. 2007;33:1050–1051.
42. Cao J, Wang Y, Shi Y, Zhang D, Zhang q, Chen L, Mao L, Wang H. HCV
genotyping for chronic patients in Nantong. Chinese medical journal of
transportation. 2005;19:75–76.
43. Miu H, Jiang L. HCV genotype distribution in the areas of southern jiangsu
and its relationship with the percentage of NK cells abnormal. Clinical
Medical Engineering. 2010;17:18–19.
44. Zang X, Yao LG, Jianwen. HCV - RNA quantitative detection and genotyping in
Changwu. China's health care nutrition ten-day periodical. 2013;23:6868–6869.
45. Chen L, Wang YS, yingjuan, Cao J, Zhang D, Mao H, Zhao J, Mao L, Wang H.
The clinical application of HCV genotyping DNA microarray and
significance. Journal of Modern Laboratory. 2005;20:8–10.
46. Yang X, Wu G. HCV genotyping and helper T cells factor expression in
peripheral blood of Wuxi, Jiangsu. J Mod Lab Med. 2012;27:73–5.
47. Wu X, Chen L. HCV genotype distribution investigation of xuzhou and the
surrounding area. Disabled Chinese Medicine. 2014;22:34-35.
48. Ding W, Shao J, Xu K, Pan J, Tan S, Deng X, Yu R, Hu X, Zhang Y. Hepatitis c
virus genotypes in Yixing area and variation of analysis. China Pub Health.
2005;21:1193–4.
49. Jiang S, Wang J: HCV epidemiological and clinical curative effect in northern
Anhui Province. Chin J Clin Hepatol 2012;28:937–940.
50. Zhou W, Qian F. HCV genotype distribution in Huzhou, Zhejiang. Surveillance
of disease. 2012;27:25–27.
51. Ding S, Zhou W, Hu A, Liang X, Weng P. Hepatitis c virus genotype points
detection in ningbo area. Chin J Health Lab Technol. 2011;21:2453–2454.
52. Xiong T, Hu A: HCV genotyping and viral load and the relevant analysis of
HCV viral load and disease progression. Disease surveillance. 2015;30:19–22.
53. Qian F, Zhou W. Application research od gene chip on HCV genotype
among chronic HCV infectors. China Preventive Medicine. 2012;13:530–532.
54. Xiong T, Hu A. Reserch on HCV genotyping The eastern region of zhejiang
province. Chinese Journal of Nosocomiology. 2015;25:5139–5141.
55. Wang M, Xu B. Phylogenetic tree analysis of HCV genotypingin chronic
hepatitis c patients. Journal of Medical Research. 2012;41:76–78.
56. Liu J, Huang Y. Hepatitis c genotype distribution characteristics and the
epidemical analysis. International Journal of Laboratory Medicine. 2010;31:
1347–1348.
57. Gui Y, Zheng H. Hepatitis c virus genotyping of jiujiang area. Experimental
and Laboratory Medicine. 2010;28:480-514.
58. Xie N, Zhu X. Micro board nucleic acid hybridization technology observation
on HCV genotyping in Jiangxi area. Acta Acad Med. Jiangxi, Acta Academiae.
2003:49-50 + 55.
59. Huang G, Chen C. PCR-RDB detection for Hepatitis c virus. The Journal of
Practical Medicine. 2006;22:1688–1690.
60. Su H, Wu X. HCV genotype distribution in Anhui. Chinese Journal of
Epidemiology. 1997;18:14–16.
61. Chen X: Molecular epidemiology research on HCV infection in some natural
village of Fujian Province. Master. Fujian Medical University. 2009.
62. Zhang J, Yin Y, Xie Y. HCV genotyping based on NS5B gene region. Chinese
journal of anti-infective chemotherapy. 2003;3:287–290.
63. Mao H, Gu S. Establish a DNA chip technology to detect hepatitis c virus
genotype and its preliminary application. The experimental and clinical
virology journal. 2003;17:77–79.
64. Li Y, Chenjianjie. HCV genotype distribution research among 71 chronic
patients in Shanghai. Combine traditional Chinese and western medicine
liver disease. 2006:360-361 + 365.
65. Jiang W, Gu S. Hepatitis c virus genotyping research in Shanghai. Chin J
Liver Dis. 1999;7:29–30.
66. Wu H, Lu Y: HCV genotyping and risk factor analysis among HCV infectors
in Pudong, Shanghai. China Preventive Medicine. 2012;13:839–843.
67. Hu D, Zhao W. HCV genotyping for 215 cases in Nanjing and Guangdong
and the association with transmission routs. Jiangsu Medical Journal. 2014;
40:597–598.
68. Rong X, Zheng Y. HCV genotyping comparation between clinical patients and
donors in Guangdong. Chinese Journal of Blood Transfusion. 2014;27:593–596.
69. Huang Z, Ke C. HCV genotype classification study among HCV infectors-
With 140 cases of test analysis. New medicine. 2012:109-111 + 141.
70. Yuan X, Chen W, Wei S. Real-time fluorescent PCR technology in the
application of hepatitis c virus genotype. Guangdong Medical Journal. 2011;
32:582–584.
71. Wei J, Zhang T. HCV gentype detection using PCR-RDB in Guangdong. J South
Med Univ 2010:2270-2272 + 2276.
72. Huang H, Zhou Y. Joint analysis of HCV species and highly conserved
sequence to determine HCv genotype in Guangdong. Guangdong Medical
Journal. 2010;31:825–828.
73. Tang W, Yang Y. HCV genotyping detection among HCV infectors in
Guangdong. Practical journal of clinical medicine. 2008;15:1373–1376.
74. Hu B, Zhang X. HCV genotyping research in HCV infectors in Guangdong.
Journal of Tropical Medicine. 2006:1071-1072 + 1127.
75. Yang G, Chen S, Cui J. Establishment of Hepatitis c virus reverse dot
hybridization genotyping method and the initial application. Chinese
Journal of Epidemiology. 2005;26:440–443.
76. An Y, Yang S, Yao J. Genotyping of HCV infectors and the association woth
clinics in Guangdong. Acad J SUMS. 1999;20:74–77.
77. Tang W, Su M. HCV genotyping distribution and epidemiological characteristics
in Guangxi. WCJD. 2014;22:1300–1306.
78. Tang W. HCV genotyping and its clinical significance in Guangxi. Master.
Guangxi Medical University. 2014.
79. Zhou J, Xiao J. HCV genotyping reaserch in Haikou. Modern Preventive
Medicine 2012:4507-4508 + 4510.
80. Cai Q, Hong C, Zhang X, Zhao Z, Gao Z. Comparation of HCV genotyping
method based on core gene and NS5B and line probe assay for chronic
patients in Guangdong. Chin J Infect Dis. 2012;30:542–7.
81. Li Y, Yang Y: HCV genotyping research among chronic patients in Zhuhai
region. Chin J Health Lab Technol 2009;19:1071–1073.
82. Liu L, Zhang R. China southern and southwestern genotype distribution
characteristics of HCV infection. China Journal of Modern Medicine. 2007;17:
2337–2340.
83. Zhang Y, Zhao D, Zhang Y. Xingtai area HCV genotype distribution and its
relationship with disease progression and sustained virological response.
Chin J Clin Hepatol. 2015;31:1845–1848.
84. Yan Y, Li Z. HCV - RNA quantitative detection and genotyping of research among
HCV infectors in Beijing. Medicine theory and practice. 2007;20:756–757.
85. Liu Z, Wei H. HCV genotyping among HCV infectors in Beijing. Chin J
Epidemiology. 2005;26:148–9.
86. Zhang M, Han T, Xiao S. Transmission routs ananlysis among chronic hepatitis
c infectors in Tianjin. Shandong Medical Journal. 2013;53:1–3.
87. Fan G, Wen W, Han J, Hu X, Chen T, Cao J. HCV RNA detection and
genotype research in Mongolian people. Practical Preventive Medicine.
2012;19:1867–1869.
88. Wang Y, Zhu Y. HCv genotyping and its clinical significnace in Taiyuan.
Practical journal of liver disease. 2010;13:109–111.
89. Wu L, Liu Y. Research on HCV genotype among different group people
in Shanxi. The Chinese journal of microbiology and immunology. 2001;
21:14–17.
Zhang et al. Virology Journal  (2017) 14:41 Page 10 of 14
90. Zhou Z, Xu H. HCV genotype distribution and its clinical significance in
Chongqing. Journal of Chongqing Medical University. 2015;40:383–387.
91. Liang Y, Yang X. HCV genotype in HCV patients in Guizhou and correlation
studies associated with the peripheral helper T cell factor expression.
Guizhou Medical Journal. 2015;39:301–303.
92. Liang Y. HCV genotype in HCV patients and the correlation ananlysis
associsted with serum viral load and Blood biochemical cytology index.
Guizhou Medical Journal. 2015;39:14–17.
93. Li Y, Bi S. Correlation analysis of hepatitis c virus genotype, viral load and
peripheral blood T lymphocyte subgroup in HCV patients of Kunming. The
Chinese journal of liver disease. 2015;23:142-144.
94. Yang X, Yue D. L, Li Y. HCV genotyping status in Guizhou. Journal of
Guiyang Medical College. 2014;39:486–489.
95. Li Z, Gao Y. HCV genotyping research based on NS5B region. International
Journal of Laboratory Medicine. 2011;32:550–552.
96. Lei H, Dai J. HCV genotype and its clinical significance among HCV patients
in Kunming. Hepatology. 2011;16:48–49.
97. Song H, Yi X. The HCV infection status in Tibet Tibetan crowd and HCV
genotype analysis. Gastroenterology and liver disease. 1997;6:315–317.
98. Gonza Yuzhen GJ. The preliminary study of hepatitis c virus (HCV) genotypes
among Tibet population. Tibetan medicine journal. 1996:9-10 + 65.
99. Zhang F, Wang X, Wang Y. HCV subtype distribution state in Chongqing.
J Fourth Mil Med Univ. 2005;26:1253–1256.
100. Liu B, Wang Y. HCV genotyping research on 69 cases in Chongqing.
Chongqing Medical Journal. 2002;31:174–175.
101. Ding L, Zhong H, Lu X, Zhou J, Liu X, Ying B. HCV genotype distribution
and relevance to the antiviral effect inSichuan people. Journal of Sichuan
University. 2015;46:573–577.
102. Liu X. Study on association between HCV viral load and genotype among
single and HIV/HCV infectors. Master. Fudan University. 2011.
103. Li B, Zhang T. Genotype distribution of HCV carriers and clinical significance
among HCV patients. Shaanxi Medical Journal. 2015;44:1375–1377.
104. Wang J. Different genotype distribution characteristics in southern Gansu.
Laboratory Medicine and Clinic. 2014;11:2364–2365.
105. Li M, Tao G. HCV genotype characteristics in Baiyin. The Western Medicine.
2014;27:63–65.
106. Yang W, Xu H. Genotypes characteristics HCV infection in four
different ethnicity of Gansu. Journal of gansu college of traditional Chinese
medicine. 2013;30:27–30.
107. Yang J, Li Z, Tian S. Relationship between the autoantibodies dynamic
change and the HCV - RNA genes. International Journal of Laboratory
Medicine. 2012;33:2960–2962.
108. Xu H, Yang W. Research on HCV genotyping Dongxiang Autonomous
County of Gansu. Molecular diagnosis and therapy. 2012;4:111–114.
109. Xu H, Ju J. HCV genotyping research in a region. International Journal of
Laboratory Medicine. 2012;33:683–684.
110. Liang C. HCV genotyping among chronic HCV ininfectors and antiviral
therapeutic effect analysis in Wuwei. Gansu Medical Journal. 2012;31:
900–902.
111. Zhang W, Liu L, Du S. HCV genotype distribution characteristics in Lanzhou,
China. Chin J Clin Hepatol. 2010:290-291 + 294.
112. Chen Q, Guo Z, Xiao P, Yang Y, Xiong Y, Yue W. HCV serotyping and
genotyping and study on the relationship with the interferon antibody in
Gansu. International Journal of Laboratory. 2006;27:612–614.
113. Peng C, Mao X. HCV genotyping annalysis of the Han chinese people in
Gansu. Chin J Clin Hepatol. 2013;29:828–831.
114. Xu H, Yang W. Research on HCV genotyping in Tibetan of Gansu.
International Journal of Laboratory Medicine. 2012:2081-2082 + 2084.
115. Li Q, Han R, Wang X. Hepatitis c genotyping situation analysis in Wuwei
area. The Chinese community physicians. 2011;13:319.
116. Liu T, Chen Z. HCV genotyping research on Uighur and han Chinese people
in Xinjiang. Chinese Journal of Nosocomiology. 2015;25:4122–4124.
117. Chen Z, Liu J, Meng C, Zhang Z, Zhang C. HCV genotyping sutdy
among han, uygur, kazak patients in Xinjiang. J Xinjiang Med Univ.
2015:855-857 + 861.
118. Xu Y, Qiu F. HCV genotyping analysis among uighurs in Xinjiang. The
Experimental and Clinical Virology Journal. 2014;28:265-267.
119. Huang Y, Han F. Epidemiological characteristics and analysis of 110 HCV
infectors. Chin J Clin Hepatol. 2014;30:505–507.
120. Abdulhalili. H, Shi G. HCV genotyping ananlysis od 118 cases in Xinjiang.
The Chinese journal of liver disease. 2011;19:127–128.
121. Zang Y, Xie Y, Xie C. Distribution state in Anshan central hospital. Journal of
Dalian Medical University. 2015:358-360 + 366.
122. Bi M, Wang X, Wang W, Chen L, Yan B, Yang B. HCV genotype and subtype
distribution distribution characteristics and clinical sgnificance in
Heilongjiang. Chinese journal of medical frontier. 2014;6:30–32.
123. Bai S. HCV genotyping of patients in Shenyang. China Practical Medical.
2009;4:54–55.
124. Sun L, Liu W. Research on HCV serum type and genetic type. J Clin Lab Sci.
2007;25:271–272.
125. Xu C, Zhang M. HCV genotyping ananlysis of 650 chronic cases in
Shenyang. The Chinese journal of liver disease. 2012;20:547-549.
126. Li X, Ma Y, Yang G. In: HCV genotyping in Jilin and its clinical significance.
China Practical Medical. 2011;6:33–34.
127. Xie Y, Xie C. Hepatitis c virus subtype distribution in Dalian. Chin J Hepatol.
2009;17:872–3.
128. Xie F, Shi Q, Wang J. HCV genotyping and its correlation with liver disease
in Changchun. Chinese Journal of Biologicals. 2009:35–37
129. Xu G. Clinical research on HCV genotyping in Jilin. Master. Jilin University. 2008.
130. Su X, Niu J. HCV genotyping investugation in Jilin. Chinese journal of public
health 1997;16:348.
131. He P, Chen C. HCV genotyping research. Journal of Medical Forum. 2010;31:
10–11.
132. Yan X, Wu W, Wei L. HCV genotyping research on 90 cases. Acta Academiae
Medicinae Xuzhou. 1997;17:14–15.
133. Chang J, Zhang Y, Wang J, Meng Y, Wang M. HCV genotyping for chronic
HCV infectors and research on relationship with HCV RNA leval. Journal of
Clinical Hepatology. 2012;15:321–323.
134. Shen L, Zhao W. Comparison of HCV distribution between donors and non-
donors in Jiangsu. Chinese Journal of Nosocomiology. 2011;21:861–863.
135. Fang Y, Dai M, Zhang Y, Yan X. Hepatitis c virus genotyping research in xuzhou
region. The experimental and clinical infection magazine 2014;8:317–320.
136. Zhang H, Zhang X, Li H. Hepatitis c virus genotyping and HCV RNA
correlation studies among chronic HCV infectors. Laboratory Medicine and
Clinic. 2014;11:3395–3397.
137. Tan G, Sun M. Hepatitis C virus genotype distribution characteristics in HCV
patients of Nanjing. Clinical Focus. 2015;30:393–396.
138. Wang j, Zhou Z. Change analysis of HCV genotype in Nanjing 2007–2014.
Medical Journal of Communications. 2014:666-668 + 670.
139. Yi D, Yu S. HCV genotyping distribution among HCV infectors in Jiangxi.
Acta Acad Med Jiangxi. 2000:39–40.
140. Zhu S, Chen H. HCV genotyping and discussion about clinical relationship
in Heilongjiang. Chinese Journal of Epidemiology. 2000;44.
141. Zhang T, Zhang S, Gao P. HCV genotyping in Lanzhou region. China Public
Health. 2000;16:166.
142. Chen Z, Xie N, Zhang Z, Meng C, Gu T, Zhao J, Zhnag C. HCV genotyping study
among han, uygur in Xinjiang. Chongqing Medical Journal. 2016:14-16 + 18.
143. Ku Q, Yu G: The association between hepatitis c gene subtype and sugar,
lipid metabolism and liver damage in Qinghai. Journal of Qinghai Medical
College. 2014;35:202–205.
144. Zhang Y, Sun H. Detecting HCV genotypes in two cities of Xinjiang using
HCV NS-5 region. Xinjiang medical journals. 1998;21:40–43.
145. Nuen ZNJZ. HCV genotyping and its clinical significance in Inner Mongolia
and Mongolia. Inner Mongolia Medical College. 2007.
146. Li Z, Jiang Y, Li H. Hepatitis c genotype distribution research on 82 HCV
infectors in Urumchi. J Xinjiang Med Univ. 2010;33:542–544.
147. Liu X, Feng H. Molecular epidemiological investigation on HCV and its clinical
significance in Linyi City. Journal of Shandong Medical College. 2013;35:11–14.
148. Hu J, Zhang M. HCV genotype analysis among anti-HCV positive donors in
Xuzhou. Journal of Modern Laboratory Medicine. 2014;29:152–153.
149. Zhu S, Shi L. HCV genotyping research among Zhejiang port entry-exit
personnel. Chinese Journal of Nosocomiology. 2013;23:3840–3842.
150. Chen Y, Sun C, Wang S. Analysis of HCV genotyping among HCV infectors
in Zhejiang. Journal of Laboratory Medicine and Clinic. 2015;12:43-45.
151. Niu J, Xu R. HCV genotype research in Hebei. VIROLOGICA SINICA. 2003;18:611–3.
152. Jin H, Lin B, Liu S. Hepatitis c virus (HCV) genotypes and the correlation of clinical
research in Tianjin. Journal of Tianjin Medical University. 2014:286-288 + 292.
153. Tan B, Li J. Epidemiological investigation of hepatitis c virus (HCV) infection
and genotyping research in Tongren. Chinese Journal of Nosocomiology.
2015;25:4125–4127.
154. Jian W, Zhang F. HCV RNA genotyping in Harbin area. Practical journal of
liver disease. 1997;2:225–226.
Zhang et al. Virology Journal  (2017) 14:41 Page 11 of 14
155. Deng L, Gui X, Gao S, Xiong Y, Yang R, Chi M. HCV genotyping among HIV
infected population transmitted by blood transfusion in some region of
Hubei. Chin J Gen Pract. 2012;11:441–3.
156. Zheng J, Liu Y. Research on HCV genotyping among IDUs in Jiangsu.
Journal of Medical Postgraduates. 2011;24:816–820
157. Cui L. Research on HCV genotype distribution among population being
monitored with HIV/AIDS in Anhui. Master. Anhui Medical University. 2015.
158. Lin R, Wag B. HCV genotype distribution characteristics ans its clinical
significance in Wenzhou. China Medical Herald. 2014;11:58–60.
159. Li J, Xie N. HCV genotypes research in patients infected with HIV/HCV using
chip technology. Experimental and Laboratory Medicine. 2014;32:395–397.
160. Pu X, Hang S. HCV genotyping and clinical ananlysis in Changzhou. Journal
of Radioimmunology. 2012;25:663–665.
161. Liu J, Huang Y. HCV genotype ananlysis of 41 chronic HCV IDUs. Laboratory
Medicine and Clinic. 2011;23:2914–2915.
162. Zheng JF, Liu Y. A research on HCV genotype distribution among IDU in
Jiangsu. Journal of Medical Postgraduates. 2011;24:816–820.
163. Yang Y. The full-length seguence ananlysis of HIV-1main strain and HCV
genotyping among HIV/HCV coinfectors in Shanghai. Master. Second
Military Medical University. 2009.
164. Wen J, Duan Z. Research on HCV genotype among 62 cases in Wenzhou.
Journal of clinical hematology. 2009:70–72
165. Li X. HCV genotype research in southern anhui. Master. Anhui Medical
University. 2009.
166. Gong J, Yang J. Common HCV genotype classification study among IDUs in
Nanjing. Southeast of the national defense medical. 2009;11:199–201.
167. Liao Q, Xu R. The association between HCV genotype and viral load among
unpaid blood donors positive to anti-HCV in Guangzhou. Chin J Immunol.
2012;28:242–245.
168. Wang M, Xu R. HCVE1 and NS5B gene sequencing and genotyping among
unpaid donors in Guangdong. Chinese Journal of Blood Transfusion. 2011;
24:201–205.
169. Ye H, Xu R, Wang M. HCV genotyping study among unpaid donors in
Guangzhou. J South Med Univ. 2010;30:2655–2657.
170. Ge X, Wang S. HCV infection among IDUs in Guangxi and its molecular
biology research. Guangxi Journal of Preventive Medicine. 1996;2:1–7.
171. Kuang Y, Huang X. HCV genotypes in 209 intravenous drug users positive
to HIV-1. South China preventive medicine. 2015;41:124–131.
172. Rong X, Xu R. Epidemiological characteristics of hepatitis c virus (HCV)
among unpaid donors in Guangzhou, 2009–2011. Chinese Journal of Viral
Diseases. 2013;3:362–366.
173. Zhong Q, Liu Z. HCV genotyping study among IDUs in Guangzhou. Chin J
Misdiagnostics. 2012;12:3796–8.
174. Liao Q. Molecular epidemiology research on HCV infection among
volunteers in Guangzhou. Master. Chongqing Medical University. 2012.
175. Huang T, Rong X. HCV genotyping and virus drops degree correlation
studies among volunteers in Guangdong. Chinese Journal of Blood
Transfusion. 2012;25:1063–1065.
176. Wang M, Xu R, Rong X. HCV sequencing and genotyping based on E1 and
NS5B among voluntary blood donors in Guangzhou. Chinese Journal of
Blood Transfusion. 2011;24:201–205.
177. Fu Y, Wang Y, Xia W, Pybus OG, Qin W, Lu L, Nelson K. New trends of HCV
infection in China revealed by genetic analysis of viral sequences determined
from first-time volunteer blood donors. J Viral Hepat. 2011;18:42–52.
178. Wang Y. Molecular epidemiological studies among unpaid blood donors in
Guangzhou and new subtype identification of 6 v. Sun Yat-sen University.
2009.
179. Wang M, Zhou Y, Chen F: Determination of the nucleotide sequence and
genotyping among unpaid donors in Yunnan and Shanxi. Chinese Journalof
Blood Transfusion. 2009;22:875–879.
180. Huang C, Zhou J. HCV subtype investigation in a illegal blood village in
Hebei. Exp Clin Virol J. 2009;23:8–10.
181. Huang C. Serological and molecular epidemiological investigation on
HCV in some ‘blood donation village’ in Hebei. Master. Hebei Medical
University. 2009.
182. Wu L, Liu Y: HCV genotyping ans sequence ananlysis among IDUs in Shanxi.
China Preventive Medicine 2002;3:37–40.
183. Ding X, Gu H, Zhong ZH, Zilong X, Tran HT, Iwaki Y, Li TC, Sata T, Abe
K. Molecular epidemiology of hepatitis viruses and genotypic
distribution of hepatitis B and C viruses in Harbin, China. Jpn J Infect
Dis. 2003;56:19–22.
184. Jia G, Liu Y. HCV genotyping among unpaid blood donation population in
Xianyang. Clinical blood transfusion and inspection. 2015;17:331–334.
185. Abla A, Abdurishid G, Mamt D, Rouzi A, Ca M, Adical P, Ni MJ, Li M,
TaHr: HIV infected Kuqa Uighur population coinfected with HCV and
the determination of the subtype. For disease control and prevention.
2015;30:5–8.
186. Kou J, Lei C. HCV genotypes investigation among paid donors in Dingxi,
Gansu. Gansu Medicine. 2013;32:377–379.
187. Xu R, Fang J. HCV molecular epidemiology research among unpaid donors
in northwest. Chinese Journal of Blood Transfusion. 2009;22:880–883.
188. Zhang Z. HCV molecular epidemiology research on IDUs in Yunnan. Master.
Peking Union Medical College. 2014.
189. Zhang SQ, Wang YL, Li XF. Chracteristics of HCV genotyping and analysis of
the spreading trend in patient cofected with HIV and HCV. International
Journal of Laboratory Medicine. 2014;35:920–922.
190. Wang J, Wang J. HCV genotyping among HIV infectors in Dali, Yunnan. Journal
of Pathogen Biology. 2014;9:131–134.
191. Zhang Z, Yao Y, Wu W, Feng R, Wu Z, Cun W, Dong S. Hepatitis C virus
genotype diversity among intravenous drug users in Yunnan Province,
Southwestern China. PLoS One. 2013;8:e82598.
192. Su L, Qin G. Molecular research on HCV genotype among HIV/HCV
coinfection infectors in Liangshan. Journal of Preventive Medicine
Information. 2013;29:548–552.
193. Wang Z, Yuan X. Hepatitis c virus genotype distribution and epidemiological
characteristics in Liuta rural area, Puyang City, Henan. Disease surveillance.
2013;28:560–563.
194. Tao J, Liu Y. HCV genotyping research among IDUs in Guizhou. Chinese
Journal of Viral Diseases. 2012;2:117–122.
195. Pu D, Wang Y. Hepatitis c virus genotype characteristics among HIV/HCV
infectors in Kunming. China Tropical Medicine. 2011;11:662–664.
196. Zhao S, Li B. Epidemiology investigation of HCV among unpaid donors in
Chongqing. Chongqing Medical Journal. 2006:964-966 + 968.
197. Fang Y, Chen S, Wang Y, Li C. Investigation on infection status of IDUs in
Chongqing. Chin J Drug Depend. 2001;10:220–222.
198. Chen M, Ma Y, Luo H, Chen H, Lu R, Dai J, Song L, Yang C, Mei J. Analysis of
HCV genotyping among IDU in Kunming. Chin J Epidemiol. 2015;36:994-997.
199. Wang Y, Yu Q. HCvgenotyping among HCV patients in Qingdao. Preventive
Medicine Tribune. 1998;4:331–331.
200. Zhao SM, Jiang TL, Li RQ, Gao FX, Lu L, Zheng HQ, Hu J, Fan YH, Li B, Xiao
RQ, Yury K. HCV infection in voluntary donors and its influence on
recruitment of donors in Chongqing area. Zhongguo Shi Yan Xue Ye Xue
Za Zhi. 2008;16:676–80.
201. Zhao J. HIV/HCV infection among high-risk population in Central and western
China and preliminary analysis of HCV subtypes. Master. Chinese Center for
Disease Control and Prevention. 2009.
202. Zeng J, Yang g, Chen s, Cui J. HCV genotyping in Foshan and the association
with HCV voral load study. Chin J Health Lab Technol. 2013:3564-3565 + 3573.
203. Zhang J, Yang L. HCV genotyping and is clinical significance in Shijiazhuang.
Medical frontier. 2012;2:178-179.
204. Nolte FS. Hepatitis C virus genotyping: clinical implications and methods.
Mol Diagn. 2001;6:265–77.
205. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C.
Hepatology. 2002;36:S65–73.
206. Murphy DG, Willems B, Deschenes M, Hilzenrat N, Mousseau R, Sabbah S.
Use of sequence analysis of the NS5B region for routine genotyping of
hepatitis C virus with reference to C/E1 and 5’ untranslated region
sequences. J Clin Microbiol. 2007;45:1102–12.
207. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus:
quasispecies and genotypes. Semin Liver Dis. 1995;15:41–63.
208. McOmish F, Yap PL, Dow BC, Follett EA, Seed C, Keller AJ, Cobain TJ, Krusius
T, Kolho E, Naukkarinen R, et al. Geographical distribution of hepatitis C
virus genotypes in blood donors: an international collaborative survey.
J Clin Microbiol. 1994;32:884–92.
209. Fu Y, Qin W, Cao H, Xu R, Tan Y, Lu T, Wang H, Tong W, Rong X, Li G, et al.
HCV 6a prevalence in Guangdong province had the origin from Vietnam
and recent dissemination to other regions of China: phylogeographic
analyses. PLoS One. 2012;7:e28006.
210. Lu L, Nakano T, He Y, Fu Y, Hagedorn CH, Robertson BH. Hepatitis C
virus genotype distribution in China: predominance of closely related
subtype 1b isolates and existence of new genotype 6 variants. J Med
Virol. 2005;75:538–49.
Zhang et al. Virology Journal  (2017) 14:41 Page 12 of 14
211. Wang Y, Xia X, Li C, Maneekarn N, Xia W, Zhao W, Feng Y, Kung HF, Fu Y, Lu
L. A new HCV genotype 6 subtype designated 6v was confirmed with three
complete genome sequences. J Clin Virol. 2009;44:195–9.
212. Xia X, Lu L, Tee KK, Zhao W, Wu J, Yu J, Li X, Lin Y, Mukhtar MM, Hagedorn
CH, Takebe Y. The unique HCV genotype distribution and the discovery of a
novel subtype 6u among IDUs co-infected with HIV-1 in Yunnan, China.
J Med Virol. 2008;80:1142–52.
213. Xia X, Zhao W, Tee KK, Feng Y, Takebe Y, Li Q, Pybus OG, Lu L. Complete
genome sequencing and phylogenetic analysis of HCV isolates from China
reveals a new subtype, designated 6u. J Med Virol. 2008;80:1740–6.
214. Xu R, Tong W, Gu L, Li C, Fu Y, Lu L. A panel of 16 full-length HCV genomes
was characterized in China belonging to genotypes 1–6 including subtype
2f and two novel genotype 6 variants. Infect Genet Evol. 2013;20:225–9.
215. Su Y, Liu H. Hepatitis c virus genotype distribution in China. Chin J
Epidemiol. 2013;34:80–4.
216. Zhang C, Wu N, Liu J, Ge Q, Huang Y, Ren Q, Feng Q, He G. HCV subtype
characterization among injection drug users: implication for a crucial role of
Zhenjiang in HCV transmission in China. PLoS One. 2011;6:e16817.
217. Dong ZX, Zhou HJ, Wang JH, Xiang XG, Zhuang Y, Guo SM, Gui HL, Zhao
GD, Tang WL, Wang H, Xie Q. Distribution of hepatitis C virus genotypes in
Chinese patients with chronic hepatitis C: correlation with patients’
characteristics and clinical parameters. J Dig Dis. 2012;13:564–70.
218. Nie H, Chen J. Hepatitis c virus genotype distribution of research on
Chinese han population with chronic HCV infection. Chin J Epidemiol.
2012;33:501–4.
219. Ge X, Wang S, Li D, Mizokami M, Wu R, Huang G, Li Y, Wang Y, Wang Y, Cao
K, et al.: Molecular biology research on HCV serologica genotype and
suntypes in IDUs, patients and blood donors in Guangxi. The experimental
and clinical virology journal 1996;2:312–317.
220. Chen YD, Liu MY, Yu WL, Li JQ, Peng M, Dai Q, Liu X, Zhou ZQ. Hepatitis C virus
infections and genotypes in China. Hepatobiliary Pancreat Dis Int. 2002;1:194–201.
221. Wang y, Chen c: Hepatitis c genotyping and clinical significance In The fifth
national clinical liver disease and the tenth anniversary of the founding of
the Chinese journal of liver disease academic conference proceedings. 2006
222. Yuen MF, Lai CL. Response to combined interferon and ribavirin is better in
patients infected with hepatitis C virus genotype 6 than genotype 1 in
Hong Kong. Intervirology. 2006;49:96–8.
223. Xu R, Wang M, Qiu Y. C: Hepatitis c virus (HCV) infection with different
genotypes in China. Chinese Journal of Viral Diseases 2015;5:11–16.
224. Wang J, Tang S: HCV genotyping among HCV patients with different
transmission routs. China Public Health. 2013;29:809–811.
225. Chen W, Nie J, Cai W, Yuan X, Hu F, Wei S, Tang Y, Zhnag F, Tang X. Analysis of
HCV genotyping among patients infected with single HCV and HIV/HCV. Chin
J Liver Dis. 2011;19:729–33.
226. Zhao R, Peng J, Tang L, Huang H, Liu M, Kong W, Pang B. Epidemiological
distribution and genotype characterization of hepatitis C virus and HIV co-
infection in Wuhan, China, where the prevalence of HIV is low. J Med Virol.
2013;85:1712–23.
227. Li WQ, Yuan ZH, Xu GH, Wu DL. Hepatitis c genotyping progress and its
clinical significance. World Chinese Journal of Digestology. 2009;17:589–593.
228. Lu L, Wang M, Xia W, Tian L, Xu R, Li C, Wang J, Rong X, Xiong H, Huang K,
et al. Migration patterns of hepatitis C virus in China characterized for five
major subtypes based on samples from 411 volunteer blood donors from
17 provinces and municipalities. J Virol. 2014;88:7120–9.
229. Huang JT, Xia R, Xiong HP, Xu R, Huang K. Correlation study of HCV
genotype and viral load among voluntary blood donors in Guangzhou.
Chinese journal of blood transfusion. 2012;28:1063–1065.
230. Chen J, He YC. genotyping characteristics and significance in Maintenance
hemodialysis patients infected with hepatitis c virus. Chinese Journal of
Blood Purification. 2013;12:282–286.
231. Yang JY, Ye XL, Cheng SQ. Some questions on HCV genotype in patients
transmitted by hemodialysis. Chinese Journal of Viral Diseases. 2014;4:235–239.
232. Ye Y. Hepatitis c epidemic characteristics in fujian province and the
construction and application of cell culture model in vitro. Doctor. Fujian
Medical University. 2011.
233. Simmonds P. Reconstructing the origins of human hepatitis viruses. Philos
Trans R Soc Lond B Biol Sci. 2001;356:1013–26.
234. Xiong T, Hu AR, Jiang SW, Ding SX. Correlation analysis of HCV genotype
and viral load and disease progression. Disease Surveillance. 2015;30:19–22.
235. Li Z: HCV genotype and subtype research among 78 HCV infectors in
Urumchi. Master. Xinjiang Medical University. 2010.
236. Chakravarti A, Dogra G, Verma V, Srivastava AP. Distribution pattern of
HCV genotypes & its association with viral load. Indian J Med Res. 2011;
133:326–31.
237. Huang JT, Xiong HP, Xu R, Huang K, Wang M, Fu YS. The correlation analysis
of HCV genotype viral load among voluntary blood donors in Guangzhou.
Chinese Journal of Blood Transfusion. 2012;25:1063–1065.
238. Yue QH, Zhang XQ, Shang Y, Chen YZ, Sun WL, Su MQ, Mu SJ, Hao XK, Hu
XB. Anti-HCV reactive volunteer blood donors distribution character and
genotypes switch in Xi'an, China. Virol J. 2010;7:186.
239. Rong X, Lu L, Wang J, Xiong H, Huang J, Chen J, Huang K, Xu R, Wang M,
Zhang X, et al. Correlation of viral loads with HCV genotypes: higher levels
of virus were revealed among blood donors infected with 6a strains. PLoS
One. 2012;7:e52467.
240. Kryczka W, Brojer E, Zarebska-Michaluk D, Medynska J, Urbaniak A. Factors
influencing natural history of chronic hepatitis C. Med Sci Monit. 2001;7
Suppl 1:212–6.
241. Riaz S, Bashir MF, Haider S, Rahid N: Association of genotypes with viral
loadand biochemical markers in HCV-infected Sindhi patients. Braz J Microbiol
2016;47:980-986.
242. Ali A, Nisar M, Ahmad H, Saif N, Idrees M, Bajwa MA. Determination of HCV
genotypes and viral loads in chronic HCV infected patients of Hazara
Pakistan. Virol J. 2011;8:466.
243. Ali IM, R A: Distribution pattern of HCV genotypes and its significance with
viral load. IJMRHS 2013, 2:569–576
244. Liang YD, Yang XL, Zhang L, Xiong JF, Hong ZP, Huang H. The correlation
analysis of HCV genotype and viral load and Biological cytology index in
serum/blood in Guiyang. Guizhou Medical Journal. 2015;39:14–17.
245. Nie HM, Chen JJ, Dong HL. Analysis of clinical characteristics of the infection
of HCV genotype 1 and non-genotype 1 in China. Journal of Clinical
Hepatology. 2012;28:439-442.
246. Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its
natural history and histological progression. Am J Gastroenterol. 2002;97:
700–6.
247. Lee CM, Hung CH, Lu SN, Wang JH, Tung HD, Huang WS, Chen CL, Chen
WJ, Changchien CS. Viral etiology of hepatocellular carcinoma and HCV
genotypes in Taiwan. Intervirology. 2006;49:76–81.
248. Xie Y, Xie C. The research progress of hepatitis c virus genotyping. Journal
of Dalian Medical University. 2010;32:470–474.
249. Wang L, Xu DP, Zhang LX. HCV genotyping and clinical significance.
Hepatology. 2006;11:416–417.
250. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S,
Younossi Z, Albrecht J. Effect of treatment with peginterferon or interferon
alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.
Hepatology. 2003;38:75–85.
251. Farci P, Purcell RH. Clinical significance of hepatitis C virus genotypes and
quasispecies. Semin Liver Dis. 2000;20:103–26.
252. Rao HY, Sun DG, Yang RF, Liu F, Wang J, Feng B, Wu N, Fang JL, Song GJ,
Ma H, et al. Outcome of hepatitis C virus infection in Chinese paid plasma
donors: a 12-19-year cohort study. J Gastroenterol Hepatol. 2012;27:526–32.
253. Lee CM, Hung CH, Lu SN, Changchien CS. Hepatitis C virus genotypes: clinical
relevance and therapeutic implications. Chang Gung Med J. 2008;31:16–25.
254. Xu K, Deng XZ. HCV genotyping in Yixing, Jiangsu Province. Chinese Journal
of Epidemiology. 2005;26:73–75.
255. Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is
associated with an increased risk of cirrhosis and hepatocellular cancer in a
national sample of U.S. Veterans with HCV. Hepatology. 2014;60:98–105.
256. Larsen C, Bousquet V, Delarocque-Astagneau E, Pioche C, Roudot-Thoraval
F, Committee HCVSS, Group HCVS, Desenclos JC. Hepatitis C virus genotype
3 and the risk of severe liver disease in a large population of drug users in
France. J Med Virol. 2010;82:1647–54.
257. Dua A, Desai SS, Kumar N, Heller J. Epidemiology and treatment strategies
of iliac vein thrombophlebitis. Vascular. 2015;23:599–601.
258. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales Jr FL,
Haussinger D, Diago M, Carosi G, Dhumeaux D, et al. Peginterferon alfa-2a plus
ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–82.
259. Zhao S, Liu E, Yu H, Yang H, Xun M, Xue X, Song J, Xu K, Chu Y. Comparison
of peginterferon and interferon in treating Chinese patients with chronic
hepatitis C. Hepatogastroenterology. 2008;55:1047–54.
260. Bi MR, Kang L, Zhang K, Yang BS: Clinical significance of different HCV
genotypes and discussion about treatment effect of interferin. Chinese
Journal of Frontier Medical Science. 2015;7:76–79.
Zhang et al. Virology Journal  (2017) 14:41 Page 13 of 14
261. Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, Tateishi R,
Hamid SS, Chuang WL, Chutaputti A, et al. APASL consensus statements
and management algorithms for hepatitis C virus infection. Hepatol Int.
2012;6:409–35.
262. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American
Association for Study of Liver D. An update on treatment of genotype 1
chronic hepatitis C virus infection: 2011 practice guideline by the American
Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–44.
263. Saito T, Ito T, Ishiko H, Yonaha M, Morikawa K, Miyokawa A, Mitamura K.
Sequence analysis of PePHD within HCV E2 region and correlation with
resistance of interferon therapy in Japanese patients infected with HCV
genotypes 2a and 2b. Am J Gastroenterol. 2003;98:1377–83.
264. Hazari S, Taylor L, Haque S, Garry RF, Florman S, Luftig R, Regenstein F, Dash
S. Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon
resistance in hepatitis C virus replicon. Virol J. 2007;4:89.
265. Afzal S, Idrees M, Akram M, Awan Z, Khubaib B, Aftab M, Fatima Z,
Badar S, Hussain A. Mutations in the E2-PePHD region of hepatitis C
virus genotype-3a and correlation with response to interferon and
ribavirin combination therapy in Pakistani patients. Virol J. 2010;7:377.
266. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the
interferon-inducible protein kinase PKR by HCV E2 protein. Science. 1999;
285:107–10.
267. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ. 2014;348:g3308.
268. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and
challenges. Gastroenterology. 2014;146:1176–92.
269. Lee R, Kottilil S, Wilson E. Sofosbuvir/velpatasvir: a pangenotypic drug to
simplify HCV therapy. Hepatology International, 2016:1-10.
270. Antón J M M. Abstracts of the 25th Annual Conference of APASL, February
20-24, 2016, Tokyo, Japan. Hepatology International, 2016;10:1-506.
271. Gan XM, Li W. Opportunities and challenges of HCV treatment. Journal of
kunming medical university. 2014;35:1–3.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Zhang et al. Virology Journal  (2017) 14:41 Page 14 of 14
